MVM Winter 2020 Newsletter

Winter 2020 Newsletter

MVM team news

MVM invests in Paragon 28

MVM invests in GT Medical

SkyCell joins Abu Dhabi and Etihad to form the Hope Consortium

Valneva agrees to provide 190 million COVID-19 vaccines doses for UK

Patient Connect sees increased demand for point-of-care messaging

MVM Team News

MVM welcomes a new Partner, Jack Tanaka. Prior to MVM, he was a consultant at Bain & Company, where he served global pharmaceutical and medtech clients, specialized in assisting private equity firms in the healthcare and life science sectors.

Prior to consulting, Jack practiced medicine in the UK. He completed his MBBS at King’s College London and holds a Masters in Mathematics from the University of Oxford.

New Deals

Paragon 28

MVM invested $77 million in Paragon 28 during H2. Denver-based Paragon 28 was established in 2010 to address the unserved needs within foot and ankle surgery. Over the past ten years, the company has developed an extensive portfolio of innovative products that are specifically engineered for lower extremities. Paragon 28 is currently the world’s largest pure-play foot and ankle company and is at the forefront of improving outcomes in this fast-developing specialty.

The global foot and ankle implant market is worth $3 billion today and is one of the fastest growing segments of orthopedics. This growth is driven by an aging population that is increasingly active and mobile in old age, an increasing number of orthopedic surgeons specializing in foot and ankle surgery, and new procedures that have improved options and outcomes for patients.

In July 2020, Paragon received FDA approval for its best-in-class total ankle replacement.

GT Medical Technologies

Brain cancer tragically affects 275,000 patients annually in the US alone. Despite advances in care in many other forms of cancer, only 1 in 3 brain cancer patients live beyond five years.

Following surgical resection of a brain tumor, the current standard of care is high-energy radiation from an external source to eliminate remaining tumor cells. Although effective, external radiation traverses brain tissue en route to the tumor site, limiting total dose. By contrast, GT’s GammaTile product is placed directly on the tumor bed at the time of surgery, resulting in decreases in the key problems associated with current treatment: tumor recurrence (particularly for large tumors), debilitating side effects, and the need for follow-up visits. Phoenix-based GT uses Cesium-131 which delivers a high radiation dose over a short range and decays quickly over a few weeks, maximising the therapeutic ratio and limiting damage to healthy brain tissue.

Uptake of GammaTile is growing fast in major US brain surgery centres, bolstered by significant inbound demand from patients.

Developments in the portfolio

SkyCell joins Abu Dhabi and Etihad to form the Hope Consortium

The Hope Consortium is a public-private partnership that aims to handle more than six billion doses of COVID-19 vaccine in 2021. Abu Dhabi will use its position as a global logistics hub to distribute vaccine where it is needed around the world. SkyCell will supply the crucial temperature-controlled containers to ensure vaccines are maintained at cold or ultra-cold temperatures throughout their journey. SkyCell will also establish a regional service and manufacturing centre in Abu Dhabi, which will help support its growth. The Hope Consortium is an ambitious initiative that should have a significant impact on SkyCell’s business and humanity’s recovery from the pandemic. Click here for the full press release.

Valneva agrees to provide 190 million COVID-19 vaccines doses for UK

In September Valneva announced a partnership with the UK government to provide up to 190m doses of its COVID-19 vaccine. The total value of the deal is €1.4bn which will help to fund the manufacturing facility expansion and clinical development. Unlike many other COVID-19 vaccines, Valneva’s product is based on an established vaccine technology platform and benefits from existing commercial scale manufacturing capacity.

Patient Connect sees increased demand for point-of-care messaging

As a result of COVID-19, doctors are getting far fewer interactions with companies who are attempting to launch new and better pharma therapies. Patient Connect offers companies and other organizations such as governments the option to connect with doctors and pharmacists throughout the world at the point of care. Patient Connect is networked into 260,000 pharmacies and 834,000 clinicians. In particular, it offers access to 350 million patients in Europe where it has unparalleled expertise in navigating the many different regulatory regimes. Patient Connect has seen a 300% increase in inbound demand from clients since the pandemic began.